@Mikeptyg@JNap5C@semodough Right, they are not a dilution machine. When they did their 10-1 reverse split they had 12 million shares outstanding. They now have 84 million shares outstanding. Don't post if you have no clue what you are posting about. They also failed their NPDR trial.
@CaseyVSilver Right, I am sure if you ask Wet AMD patients if they would prefer an implant every nine months or a needle every two month in the eye, they would overwhelmingly go for the two month shot.
@Andrew99Blue@HackermanAce Yes, one or two years down the line. You say it is happening next week. They will raise when the stock pops on the FDA accepting their application for Axpaxli.
@Tiana_Celine_23 I am old and have seen scores of concerts. Journey and Heart were the best live concerts that I have seen. Steve Perry and Ann Wilson were actually better live than on record.
@zipjet When you think about it from the FDA standpoint, they want to make sure that Axpaxli is non-inferior before approving it. I can see OCUL applying anytime before the end of April, the FDA accepting the application in June and And giving a PDUFA date at the end of next April.
@Mikeptyg@Sjfms1Steven That low share count is a result of a 10-1 reverse split. After the split they had 12 million shares. They have 84 million now. Their drug failed the NPDR trial. Their drug leaves the remnants of the drug's vehicle for 18-24 months after the drug is absorbed.